Technical Analysis for RETA - Reata Pharmaceuticals, Inc. - Class A

Grade Last Price % Change Price Change
grade B 87.13 -6.94% -6.50
RETA closed down 6.94 percent on Friday, March 22, 2019, on 1.19 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical RETA trend table...

Date Alert Name Type % Chg
Mar 22 20 DMA Resistance Bearish 0.00%
Mar 22 Bollinger Band Squeeze Range Contraction 0.00%
Mar 22 Stochastic Reached Oversold Weakness 0.00%
Mar 22 Multiple of Ten Bearish Other 0.00%
Mar 22 BB Squeeze + Lower Band Touch Range Contraction 0.00%
Mar 22 Below Lower BB Weakness 0.00%
Mar 22 Lower Bollinger Band Touch Weakness 0.00%
Mar 22 Oversold Stochastic Weakness 0.00%
Mar 21 20 DMA Resistance Bearish -6.94%
Mar 21 Bollinger Band Squeeze Range Contraction -6.94%

Older signals for RETA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company focuses on drugs with novel mechanisms of action that modulate regulatory proteins called transcription factors. Its lead product candidates include bardoxolone methyl and RTA 408, which are members of a class of small molecules called antioxidant inflammation modulators. It is involved in LARIAT, a Phase II study of bardoxolone methyl for the treatment of pulmonary arterial hypertension and pulmonary hypertension due to interstitial lung disease. RTA 408 is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia and mitochondrial myopathies. Reata Pharmaceuticals, Inc. was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas.
Medicine Diseases Inflammation Health Care Pulmonary Arterial Hypertension Pulmonary Hypertension Myopathy Friedreich's Ataxia Interstitial Lung Disease
Is RETA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 5 bullish, 0 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 104.53
52 Week Low 19.31
Average Volume 213,239
200-Day Moving Average 67.996
50-Day Moving Average 85.047
20-Day Moving Average 93.698
10-Day Moving Average 92.946
Average True Range 4.7015
ADX 36.16
+DI 18.1069
-DI 17.8533
Chandelier Exit (Long, 3 ATRs ) 90.4255
Chandelier Exit (Short, 3 ATRs ) 98.2145
Upper Bollinger Band 100.2936
Lower Bollinger Band 87.1024
Percent B (%b) 0.0
BandWidth 14.078422
MACD Line 1.8546
MACD Signal Line 3.154
MACD Histogram -1.2994
Fundamentals Value
Market Cap 2.27 Billion
Num Shares 26.1 Million
EPS -1.06
Price-to-Earnings (P/E) Ratio -82.20
Price-to-Sales 15.55
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 97.35
Resistance 3 (R3) 98.45 96.16 95.64
Resistance 2 (R2) 96.16 93.56 95.60 95.07
Resistance 1 (R1) 91.64 91.95 90.50 90.54 94.51
Pivot Point 89.35 89.35 88.77 88.79 89.35
Support 1 (S1) 84.83 86.75 83.69 83.73 79.75
Support 2 (S2) 82.54 85.14 81.98 79.19
Support 3 (S3) 78.02 82.54 78.62
Support 4 (S4) 76.92